Cargando…

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited Pierre Fabre to submit evidence for the clinical and cost-effectiveness of encorafenib with binimetinib (Enco + Bini) versus dabrafenib with trametinib (Dab + Tram) as a first-lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houten, Rachel, Greenhalgh, Janette, Mahon, James, Nevitt, Sarah, Beale, Sophie, Boland, Angela, Lambe, Tosin, Dundar, Yenal, Kotas, Eleanor, McEntee, Joanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895893/ https://www.ncbi.nlm.nih.gov/pubmed/32291725 http://dx.doi.org/10.1007/s41669-020-00206-x

Ejemplares similares

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Lambe, Tosin, et al.
Publicado: (2018)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
por: Boccaccino, A., et al.
Publicado: (2022)

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2023)

Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
por: Gravbrot, Nicholas, et al.
Publicado: (2019)

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
por: Huijberts, Sanne C. F. A., et al.
Publicado: (2020)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
por: Fleeman, Nigel, et al.
Publicado: (2019)

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
por: Kopetz, S., et al.
Publicado: (2022)

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
por: Van Cutsem, Eric, et al.
Publicado: (2019)

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2022)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2018)

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF(V600E) Protein
por: Marini, Elisabetta, et al.
Publicado: (2022)

NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
por: Kobayashi, Shin, et al.
Publicado: (2023)

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines
por: Patel, Vikas, et al.
Publicado: (2021)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2020)

A systematic review of health state utility values for thyroid cancer
por: Houten, Rachel, et al.
Publicado: (2020)

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib
por: Ross, Kayleigh C., et al.
Publicado: (2018)

Impact of encorafenib on survival of patients with BRAF(V600E)-mutant metastatic colorectal cancer in a real-world setting
por: Zurloh, M., et al.
Publicado: (2023)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study
por: Hefnawy, Mohamed M., et al.
Publicado: (2022)

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2021)

Nursing care and management of adverse events for patients with BRAF(V600E)-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review
por: Fowler, Matthew, et al.
Publicado: (2023)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
por: Eriksen, Martina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_avchfgh7su8lfgj8sjjs20h61l